Health and Healthcare
2 Large Cap Biotech Leaders Pay Big Dividends and Have Huge Upside Potential
Published:
We cover dividend stocks often at 24/7, as they have provided investors with much better income streams than U.S. government and corporate bonds have over the past five years. The usual suspects often are written about as great buy-and-hold ideas, like telecommunications, utilities, consumer staples and real estate investment trusts because the dividends are dependable. However, some of those stocks lack big upside potential and are considered more of a bond proxy to many investors.
[in-text-ad]
One area that often is ignored by growth and income investors is biotechnology, as the volatility in the segment (especially with companies that have only one or two income-producing therapies or drugs) is sometimes deemed too risky. We found two companies that are industry leaders but their stocks have been absolutely hammered, and both pay dividends of at least 3.5%.
While not suited for conservative income investors, these stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry points. It is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.
This biotech giant remains a top stock for investors to buy and a safer way to play the massive potential growth in biosimilars. Amgen Inc. (NASDAQ: AMGN) discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
The company’s products include the following:
Shareholders receive a 3.49% dividend. BMO Capital Markets has an Outperform rating on Amgen stock, as well as a Wall Street-high $301 price target. The consensus target price is $247.45, and the final trade for Thursday came in at $206.78 a share.
[in-text-ad]
This stock is trading a very reasonable 9.53 times estimated 2021 earnings and has big-time upside potential. Gilead Sciences Inc. (NASDAQ: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in the areas of unmet medical need in the United States, Europe and elsewhere.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy and Zydelig products for the treatment of hematology, oncology and cell therapy patients.
In addition, Gilead provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences has collaboration agreements with Arcus Biosciences, Pionyr, Tizona, Tango Therapeutics, Jounce Therapeutics, Galapagos, Janssen, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Merck and Novo Nordisk.
Investors will be very happy to take a 4.22% dividend to the bank every quarter. Oppenheimer has a Buy rating, and its $100 price objective is the highest on Wall Street. The consensus target for Gilead Sciences stock is $76.03, and Thursday’s closing print was $68.15 per share.
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.